Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Victoria Vakiener Sells 10,040 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Victoria Vakiener sold 10,040 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $67.68, for a total value of $679,507.20. Following the sale, the director directly owned 35,723 shares of the company’s stock, valued at $2,417,732.64. This represents a 21.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR traded up $0.83 during trading on Tuesday, hitting $69.83. The company had a trading volume of 1,157,383 shares, compared to its average volume of 2,158,861. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $72.36. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The firm has a market capitalization of $9.49 billion, a P/E ratio of -872.77 and a beta of 1.28. The stock has a 50 day simple moving average of $49.13 and a 200 day simple moving average of $31.68.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals in the third quarter worth $29,000. Virtus Advisers LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth $34,000. Salomon & Ludwin LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth $34,000. Nisa Investment Advisors LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,308 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $52,000. 62.61% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. HC Wainwright upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Chardan Capital restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, December 1st. Morgan Stanley increased their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 26th. Finally, The Goldman Sachs Group boosted their price target on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $61.89.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.